EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Early efficacy and safety of obinutuzumab with chemotherapy in previously untreated patients with follicular lymphoma: A real-world retrospective report of the Polish Lymphoma Research Group

Ewa Paszkiewicz-Kozik, Iwona Hus, Monika Palka, Małgorzata Dębowska, Agnieszka Końska, Martyna Kotarska, Agata Tyczyńska, Monika Joks, Maja Twardosz, Agnieszka Giza, Ewa Wąsik-Szczepanek, Elżbieta Kalicińska und 12 weitere

Advances in Clinical and Experimental Medicine · 05.01.2023 · 32 (1) · 131-136

DOI: 10.17219/acem/157290 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Clinical and Experimental Medicine, online erschienen am 05.01.2023. Verfasst von Ewa Paszkiewicz-Kozik und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Lymphoid Malignancies, Maria Sklodowska-Curie National Research Institute of Oncology, Warszawa, Poland. Hauptthemen laut MEDLINE: Lymphoma, Follicular, COVID-19. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The first-line obinutuzumab-based immunochemotherapy improves the outcome of patients with follicular lymphoma (FL) compared with rituximab-based regimens. However, infusion-related reactions occur in almost half of patients during the 1st obinutuzumab administration. OBJECTIVES: The study aimed to evaluate the early effectiveness and safety of obinutuzumab-based induction regimens in a real-world setting. MATERIAL AND METHODS: Outcomes of patients diagnosed with FL and treated with obinutuzumab between January 2020 and September 2021 were analyzed. RESULTS: The study group included 143 treatment-naïve patients with FL. The median age was 52 years (range: 28-89 years); 45.1% of patients had a high-risk disease as assessed using the Follicular Lymphoma International Prognostic Index (FLIPI). Induction chemotherapy included: O-CVP (obinutuzumab, cyclophosphamide, vincristine, prednisolone) in 49.0% of patients, O-CHOP (O-CVP plus doxorubicin) in 28.7% and O-BENDA (obinutuzumab, bendamustine) in 22.4%. Complete response (CR) and partial response (PR) rates were 69.9% and 26.5%, respectively. There was no difference in response rates between different regimens (p = 0.309). Maintenance was started in 115 patients (85.2%). In the 1st cycle, obinutuzumab was administered as a single 1000-milligram infusion in 47.9% of patients, whereas in 52.1%, initial infusions were split over 2 days (100 mg/900 mg). Infusion-related reactions were reported only during the 1st administration of obinutuzumab in 9.1% of patients, with a similar incidence in those receiving the total dose on a single day or split over 2 days (p = 0.458). The most common adverse events were hematological. Five patients died from coronavirus disease 2019 (COVID-19). CONCLUSION: The early responses to induction regimens and adverse events profile were similar for every type of induction treatment. The infusion-related reactions were rare and limited to the 1st dose of obinutuzumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, FollicularCOVID-19HumansMiddle AgedRituximabRetrospective StudiesPolandAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDoxorubicinAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

chemotherapyfollicular lymphomainduction treatmentobinutuzumab

Substanzen

RituximabCyclophosphamideDoxorubicinobinutuzumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Lymphoid Malignancies, Maria Sklodowska-Curie National Research Institute of Oncology, Warszawa, Poland.
  • Department of Hematology, Institute of Hematology and Transfusion Medicine, Warszawa, Poland.
  • Department of Lymphoid Malignancies, Maria Sklodowska-Curie National Research Institute of Oncology, Kraków, Poland.
  • Department of Mathematical Modeling of Physiological Processes, Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences, Warszawa, Poland.
  • Department of Computational Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warszawa, Poland.
  • Department of Hematology and Transplantology, Medical University of Gdańsk, Poland.

Zitieren

APA

Paszkiewicz-Kozik, E., Hus, I., Palka, M., Dębowska, M., Końska, A., Kotarska, M., Tyczyńska, A., Joks, M., Twardosz, M., Giza, A., Wąsik-Szczepanek, E., Kalicińska, E., Wiśniewska, A., Morawska, M., Lewicka, B., Szymański, M., Targoński, Ł., Romejko-Jarosińska, J., Drozd-Sokołowska, J., …, & Walewski, J. (2023). Early efficacy and safety of obinutuzumab with chemotherapy in previously untreated patients with follicular lymphoma: A real-world retrospective report of the Polish Lymphoma Research Group. Advances in Clinical and Experimental Medicine, 32(1), 131-136. https://doi.org/10.17219/acem/157290

Vancouver

Paszkiewicz-Kozik E, Hus I, Palka M, Dębowska M, Końska A, Kotarska M, et al. Early efficacy and safety of obinutuzumab with chemotherapy in previously untreated patients with follicular lymphoma: A real-world retrospective report of the Polish Lymphoma Research Group. Advances in Clinical and Experimental Medicine. 2023;32(1):131-136. doi:10.17219/acem/157290

BibTeX
@article{PaszkiewiczKozik2023,
  author = {Paszkiewicz-Kozik, Ewa and Hus, Iwona and Palka, Monika and Dębowska, Małgorzata and Końska, Agnieszka and Kotarska, Martyna and Tyczyńska, Agata and Joks, Monika and Twardosz, Maja and Giza, Agnieszka and Wąsik-Szczepanek, Ewa and Kalicińska, Elżbieta and Wiśniewska, Anna and Morawska, Marta and Lewicka, Barbara and Szymański, Marcin and Targoński, Łukasz and Romejko-Jarosińska, Joanna and Drozd-Sokołowska, Joanna and Subocz, Edyta and Swoboda, Ryszard and Długosz-Danecka, Monika and Lech-Maranda, Ewa and Walewski, Jan},
  title = {Early efficacy and safety of obinutuzumab with chemotherapy in previously untreated patients with follicular lymphoma: A real-world retrospective report of the Polish Lymphoma Research Group},
  journal = {Advances in Clinical and Experimental Medicine},
  year = {2023},
  volume = {32},
  number = {1},
  pages = {131--136},
  doi = {10.17219/acem/157290}
}
Kostenlos starten →